Latest Prostate Specific Antigen News
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.
A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.
In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
Decreases in use of screening following USPSTF recommendations against routine PSA screening.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.
The odds of PSA screening were higher among blacks than non-Hispanic whites.
PSA level declined by an average of 0.68 ng/mL in the treatment group.
Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)